NCT04674956View on ClinicalTrials.gov

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

401

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Pancreatic Cancer Stage IVPancreatic Cancer Metastatic

Interventions

DRUG

Camrelizumab

PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.

DRUG

Paclitaxel(Albumin Bound) and Gemcitabine

Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.

DRUG

Placebo

Placebo, 200mg, D1; every 21 days as a cycle.

Trial Locations (6)

200025

RECRUITING

Ruijin hospital, Shanghai

200032

RECRUITING

Shanghai Cancer Center, Shanghai

RECRUITING

Zhongshan Hospital, Shanghai

200080

RECRUITING

Shanghai General Hospital, Shanghai

200127

RECRUITING

Renji hospital, Shanghai

200433

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors

lead

RenJi Hospital

OTHER

NCT04674956 - A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter